BACKGROUND: Almost 100 novel cancer medicines have been approved in Europe over the last decade. Limited public health care resources in countries in Central and Eastern Europe (CEE) call for a prioritization of access to effective medicines. We investigated how both reimbursement status and waiting time to reimbursement correlate with the magnitude of clinical benefit provided by novel medicines in four selected countries (Czechia, Hungary, Poland, and Slovakia). MATERIALS AND METHODS: A total of 124 indications of 51 cancer medicines with marketing authorization by the European Medicines Agency in 2011-2020 were included and followed up until 2022. Data on reimbursement status and waiting time to reimbursement (i.e. time from marketing authorization to national reimbursement approval) were collected for each country. Data were analyzed in relation to clinical benefit status (i.e. substantial versus nonsubstantial clinical benefit) of indications according to the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). RESULTS: The degree of reimbursement differed between countries with 64% of indications with reimbursement in Czechia, 40% in Hungary, 51% in Poland, and 19% in Slovakia. In all countries, a significantly greater proportion of indications with a substantial clinical benefit was reimbursed (P < 0.05). The median waiting time to reimbursement ranged from 27 months in Poland to 37 months in Hungary. No significant differences in waiting time in relation to clinical benefit were observed in any country (P = 0.25-0.84). CONCLUSIONS: Cancer medicines with a substantial clinical benefit are more likely to be reimbursed in all four CEE countries. Waiting times to reimbursement are equally long for medicines with or without a substantial clinical benefit, indicating a lack of prioritization of fast access to medicines delivering a substantial benefit. Incorporation of the ESMO-MCBS in reimbursement assessments and decisions could aid in better utilization of limited resources to deliver more effective cancer care.

IHE The Swedish Institute for Health Economics Lund Sweden

Maria Sklodowska Curie National Research Institute of Oncology Warsaw Poland

MSD Greece Alimos Greece

MSD Limited London UK

MSD s r o Bratislava Slovakia

Value Outcomes s r o Praha 2 Czech Republic

See more in PubMed

Hofmarcher T., Brådvik G., Svedman C., Lindgren P., Jönsson B., Wilking N. IHE; Lund, Sweden: 2019. Comparator Report on Cancer in Europe 2019 – Disease Burden, Costs and Access to Medicines. IHE Report 2019:7. 7.

Dyba T., Randi G., Bray F., et al. The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer. 2021;157:308–347. PubMed PMC

Eurostat. Causes of death statistics. https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Causes_of_death_statistics Available at.

Allemani C., Matsuda T., Di Carlo V., et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075. PubMed PMC

Hofmarcher T., Jönsson B., Wilking N. IHE; Lund, Sweden: 2014. Access to High-Quality Oncology Care Across Europe. IHE Report 2014:2. 2.

Lichtenberg F. Has medical innovation reduced cancer mortality? CESifo Econ Stud. 2014;60(1):135–177.

Lichtenberg F. The impact of new drug launches on life-years lost in 2015 from 19 types of cancer in 36 countries. J Demogr Econ. 2018;84:309–354.

Hofmarcher T., Ericsson O., Lindgren P. IHE; Lund, Sweden: 2022. Cancer in Ireland – Disease Burden, Costs and Access to Medicines. IHE Report 2022:4. 4.

Hofmarcher T., Lindgren P., Wilking N., Jonsson B. The cost of cancer in Europe 2018. Eur J Cancer. 2020;129:41–49. PubMed

Godman B., Hill A., Simoens S., et al. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):527–540. PubMed

World Health Organization . World Health Organization; Geneva, Switzerland: 2018. Technical Report: Pricing of Cancer Medicines and Its Impacts: A Comprehensive Technical Report for the World Health Assembly Resolution 70.12: Operative Paragraph 2.9 on Pricing Approaches and Their Impacts on Availability and Affordability of Medicines for the Prevention and Treatment of Cancer.

Cherny N.I., Sullivan R., Dafni U., et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) Ann Oncol. 2015;26(8):1547–1573. PubMed

Cherny N.I., Dafni U., Bogaerts J., et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017;28(10):2340–2366. PubMed

European Medicines Agency Authorisation of medicines. https://www.ema.europa.eu/en/about-us/what-we-do/authorisation-medicines Available at.

Cufer T., Ciuleanu T.E., Berzinec P., et al. Access to novel drugs for non-small cell lung cancer in central and southeastern Europe: a central European cooperative oncology group analysis. Oncologist. 2020;25(3):e598–e601. PubMed PMC

Newton M., Scott K., Troein P. EFPIA Patients W.A.I.T. Indicator 2021 Survey. IQVIA; Durham, NC: 2022.

OECD . OECD Publishing; Paris, France: 2020. Addressing Challenges in Access to Oncology Medicines.

European Medicines Agency Union Register of medicinal products for human use. https://ec.europa.eu/health/documents/community-register/html/reg_hum_act.htm?sort=a Available at.

Ministry of Health of the Slovak Republic List of reimbursed drugs (from 2016 onwards) https://www.health.gov.sk/?zoznam-kategorizovanych-liekov Available at.

Ministry of Health of the Slovak Republic Reimbursement and officially determined prices (from 2011 until 2015) https://www.health.gov.sk/?kategorizecia-a-uuc Available at.

State Institute for Drug Control List of medicines and food for special medical purposes covered by health insurance. https://www.sukl.cz/sukl/seznam-leciv-a-pzlu-hrazenych-ze-zdrav-pojisteni Available at.

Ministry of Health of Poland Announcements of the Minister of Health - list of reimbursed drugs. https://www.gov.pl/web/zdrowie/obwieszczenia-ministra-zdrowia-lista-lekow-refundowanych Available at.

The National Health Insurance Fund of Hungary. Archive - Public Medicines Register. https://neak.gov.hu/felso_menu/szakmai_oldalak/gyogyszer_segedeszkoz_gyogyfurdo_tamogatas/egeszsegugyi_vallalkozasoknak/pupha/PUPHAarch Available at.

National Legislation Database 7/2014. (I. 29.) EMMI decree on the amendment of certain pharmaceutical-related and other regulations related to the support of civil organizations. https://njt.hu/jogszabaly/2014-7-20-5H Available at.

National Legislation Database. 32/2016. (X. 27.) EMMI decree on the amendment of certain ministerial decrees on health insurance. https://njt.hu/jogszabaly/2016-32-20-5H Available at.

National Legislation Database. 35/2018. (X. 12.) EMMI decree on the amendment of ministerial decrees on the social insurance support of certain medicines. https://njt.hu/jogszabaly/2018-35-20-5H Available at.

National Legislation Database 36/2019. (XII. 30.) EMMI decree on the amendment of the ministerial decrees on the social security support of certain medicines. https://njt.hu/jogszabaly/2019-36-20-5H Available at.

National Legislation Database 55/2021. (XII. 22.) EMMI decree on the amendment of the ministerial decrees on the social security support of certain medicines. https://njt.hu/jogszabaly/2021-55-20-5H Available at.

European Medicines Agency Question and answer on the information contained within section 5.1 of the SPC on pharmacodynamic properties for pharmaceutical products. 2017. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/question-answer-information-contained-within-section-51-summary-product-characteristics_en.pdf Available at.

European Society for Medical Oncology ESMO-MCBS scorecards. https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards Available at.

European Society for Medical Oncology About the ESMO-MCBS. https://www.esmo.org/guidelines/esmo-mcbs/about-the-esmo-mcbs Available at.

Eurostat GDP per capita, consumption per capita and price level indices. https://ec.europa.eu/eurostat/statistics-explained/index.php?title=GDP_per_capita,_consumption_per_capita_and_price_level_indices Available at.

IQVIA Institute for Human Data Science . IQVIA; Parsippany, NJ: 2019. Global Oncology Trends 2019 - Therapeutics, Clinical Development and Health System Implications.

OECD/European Union . OECD Publishing; Paris, France: 2022. Health at a Glance: Europe 2022: State of Health in the EU Cycle.

Porter M.E. What is value in health care? N Engl J Med. 2010;363(26):2477–2481. PubMed

European Commission . Publications Office of the European Union; Luxembourg City, Luxembourg: 2017. Mapping of HTA National Organisations, Programmes and Processes in EU and Norway.

World Health Organization . WHO Regional Office for Europe; Copenhagen, Denmark: 2018. Medicines Reimbursement Policies in Europe.

2022. State Institute for Drug Control. SP-CAU-028 Assessment procedure for cost-effectiveness analysis [SP-CAU-028 Postup pro posuzování analýzy nákladové efektivity]https://www.sukl.cz/leciva/sp-cau-028 Available at.

Ministry of Human Resources Guidelines on conducting health economic analyses [Az Emberi Erőforrások Minisztériuma szakmai irányelve az egészség-gazdaságtani elemzések készítéséhez] Egészségügyi Közlöny. 2013;62(3):579–600.

Ministry of Human Resources Guidelines on the methodology of health technology assessment and economic evaluation [Az Emberi Erőforrások Minisztériuma szakmai irányelve az egészségügyi technológia értékelés módszertanáról és ennek keretében költséghatékonysági elemzések készítéséről] Egészségügyi Közlöny. 2017;66(3):821–842.

Ministry of Human Resources Health care guideline – on conducting and evaluating health economic analyses [Egészségügyi szakmai irányelv – Az egészség-gazdaságtani elemzések készítéséhez és értékeléséhez] Egészségügyi Közlöny. 2021;71(21):2178–2200.

Cameron D., Ubels J., Norstrom F. On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review. Glob Health Action. 2018;11(1) PubMed PMC

Skoupa J., Annemans L., Hajek P. Health economic data requirements and availability in the European Union: results of a survey among 10 European countries. Value Health Reg Issues. 2014;4:53–57. PubMed

Pažitný, Kandilaki . Pažitný & Kandilaki; Bratislava, Slovakia: 2022. Drug Policy in Broader Budgetary Context (Slovakia)

Ministry of Health of the Slovak Republic. Decree of the Ministry of Health of the Slovak Republic No. 298/2022 Coll. stipulating the details on calculation of the relevant multiple of gross domestic product for determining the value threshold for the assessed medicinal product [Vyhláška Ministerstva zdravotníctva Slovenskej republiky 298/2022 Z. z. ktorou sa ustanovujú podrobnosti výpočtu príslušného násobku hrubého domáceho produktu pre stanovenie prahovej hodnoty posudzovaného lieku] https://www.slov-lex.sk/static/SK/ZZ/2022/298/vyhlasene_znenie.html Available at.

Hammerman A., Greenberg-Dotan S., Feldhamer I., Birnbaum Y., Cherny N.I. The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel. Expert Rev Pharmacoecon Outcomes Res. 2018;18(1):119–122. PubMed

Uyl-de Groot C.A., Heine R., Krol M., Verweij J. Unequal access to newly registered cancer drugs leads to potential loss of life-years in Europe. Cancers (Basel) 2020;12(8):2313. PubMed PMC

European Federation of Pharmaceutical Industries and Associations . The Root Cause of Unavailability and Delay to Innovative Medicines: Reducing the Time Before Patients Have Access to Innovative Medicines. EFPIA; Brussels, Belgium: 2022.

Vogler S. “Ready for the future?” - Status of national and cross-country horizon scanning systems for medicines in European countries. Ger Med Sci. 2022;20:Doc05. PubMed PMC

Wild C., Langer T. Emerging health technologies: informing and supporting health policy early. Health Policy. 2008;87(2):160–171. PubMed

Janzic U., Knez L., Janzic A., Cufer T. Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia. Expert Rev Pharmacoecon Outcomes Res. 2019;19(6):717–723. PubMed

Thomson S., Everest L., Witzke N., et al. Examining the association between oncology drug clinical benefit and the time to public reimbursement. Cancer Med. 2022;11(2):380–391. PubMed PMC

Rachev B., Wilking N., Kobelt G., et al. Budget projections and clinical impact of an immuno-oncology class of treatments: experience in four EU markets. J Cancer Policy. 2021;28 PubMed

Hofmarcher T., Lindgren P., Wilking N. IHE; Lund, Sweden: 2022. Diagnosed But Not Treated: How to Improve Patient Access to Advanced NSCLC Treatment in Europe. IHE Report 2022:2. 2.

Hofmarcher T., Lindgren P., Wilking N. Systemic anti-cancer therapy patterns in advanced non-small cell lung cancer in Europe. J Cancer Policy. 2022;34 PubMed